Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Repros Therapeutics Inc (NASDAQ:RPRX)

1.57
Delayed Data
As of Jun 24
 -0.13 / -7.65%
Today’s Change
0.80
Today|||52-Week Range
8.96
+29.75%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$38.2M

Company Description

Repros Therapeutics, Inc. is a development stage company. The company operates as a biopharmaceutical company, which focuses on the development of new drugs to treat hormonal and reproductive system disorders. Its current product pipeline consists of Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in Woodlands, TX.

Contact Information

Repros Therapeutics, Inc.
2408 Timberloch Place
Woodlands Texas 77380
P:(281) 719-3400
Investor Relations:

Employees

Shareholders

Individual stakeholders9.37%
Other institutional20.51%
Mutual fund holders13.64%

Top Executives

Joseph S. PodolskiPresident, Chief Executive Officer & Director
Katherine A. AndersonSecretary, Chief Financial & Accounting Officer
Jaye L. ThompsonSenior Vice President-Clinical & Regulatory
Joachim F. WernickeChief Medical Officer